SCHEMBL1630280

SCHEMBL1630280

Cc1ccc(-c2ccc(C(C(N)=O)c3cccnc3)c(NCCc3ccccn3)n2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.40
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
PIK3CD O00329 1/20 0.37
JAK3 P52333 1/20 0.37
PTAFR P25105 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
F2 P00734 3/20 0.36
LDHA P00338 1/20 0.35
LDHB P07195 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631445 0.91 GBA1 (0.41) GBA1ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL1632360 0.90 GBA1 (0.41) GBA1ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL1632598 0.90 GBA1 (0.41) GBA1ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL1630995 0.89 GBA1 (0.48) GBA1ALDH1A1KDM4EMAPTLMNA
SCHEMBL1631871 0.89 GBA1 (0.40) GBA1KDM4EHPGDJAK3MEN1
SCHEMBL1631069 0.89 GBA1 (0.40) GBA1ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL1632189 0.88 GBA1 (0.42) GBA1ALDH1A1KDM4EMAPTLMNA
SCHEMBL1629522 0.88 SMN1; SMN2 (0.39) GBA1ALDH1A1SMN1; SMN2PIK3CDJAK3
SCHEMBL1632119 0.88 PIK3CA (0.42) GBA1PIK3CDJAK3PTAFRMEN1
SCHEMBL1629764 0.88 GBA1 (0.40) GBA1ALDH1A1SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 GBA1 4031/4885ALDH1A1 1756/4885SMN1; SMN2 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.